

MAY. 10. 2004 10:18AM AVENTIS US PAT DEPT  
TO: US USPTO GENERAL

RECEIVED  
NO. 2563 CENTRAL FAX CENTER

MAY 12 2004

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE**

**OFFICIAL**

Applicants Docket Number:  
USCA2332 US CNT

Applicants:  
BRYANT, et al.

Serial No.  
10/758,893

Filing Date:  
January 15, 2004

Title of Invention:  
Novel Compounds and Compositions as Protease Inhibitors

**CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence is being transmitted via  
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450, at 703-872-9306, on

Date of Deposit May 10, 2004

Printed Name of Person Signing Certificate Paul Irvine

Signature

Total Number of Pages Sent: 3

Attorney: George Wang

Group Art Unit:  
Examiner:

TO: Mail Stop  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,  
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit  
account (18-1982) in the name of Aventis Pharmaceuticals Inc.

- |  |   |
|--|---|
| <input type="checkbox"/> Amendment, 37 CFR _____               | <input type="checkbox"/> Fee Transmittal  |
| <input type="checkbox"/> Charge deposit account, in duplicate  | <input type="checkbox"/> Petition under 37 CFR _____  |
| <input type="checkbox"/> Extension of Time Petition            | <input checked="" type="checkbox"/> Other <u>POA and Correspondence Address</u><br><u>Indication Form</u> |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input checked="" type="checkbox"/> Other <u>Statement Under 37 CFR 3.73(b)</u>                           |
| <input type="checkbox"/> Maintenance Fee Transmittal           |   |

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this  
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

PTO/SB/81 (09-03)

Approved for use through 11/30/2005. OMB 0851-0035

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**POWER OF ATTORNEY  
and  
CORRESPONDENCE ADDRESS  
INDICATION FORM**

Application Number	10/758,893
Filing Date	January 15, 2004
First Named Inventor	Clifford M. Bryant
Title	Novel Compounds and Compositio
Art Unit	
Examiner Name	
Attorney Docket Number	USCA2332 US CNT

I hereby appoint:



Practitioners associated with the Customer Number:

05487

OR



Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:



The address associated with the above-mentioned Customer Number:

OR



The address associated with Customer Number:

05487

OR

Firm or  
Individual Name

Address

Address

City

State

Zip

Country

Telephone

Fax

I am the:



Applicant/Inventor.



Assignee of record of the entire interest. See 37 CFR 3.71.

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

## SIGNATURE of Applicant or Assignee of Record

Name

George Wang

Signature

Date

May 10, 2004

Telephone

908-231-2843

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.



\*Total of \_\_\_\_\_ forms are submitted.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/98 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Attorney Docket No. 015058-003000US

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Clifford M. Bryant, Barry A. Bunin, Erica A. Kraynack and John W. PattersonApplication No./Patent No.: 09/526,090/ 6,455,502 B1 Filed/Issue Date: March 15, 2000/ September 24, 2002Entitled: NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORSAxys Pharmaceuticalsa corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel 011448, Frame 0412, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

(NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.8)

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

February 26, 2004

Date

Wayne W. Montgomery  
Signature

Wayne W. Montgomery

Typed or printed name

Assistant Secretary

Title

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.